Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm

NEW YORK, July 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of TG Therapeutics, Inc. (NASDAQ: TGTX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.

PRNewsWire • Jul 21, 2026

TG Therapeutics Begins Phase II Study With Briumvi in Schizophrenia

TGTX initiates a phase II study evaluating Briumvi in adult patients with treatment-resistant schizophrenia. Shares rise.

Zacks Investment Research • Jul 7, 2026

TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia

Phase 2 trial to evaluate the effects of B-cell depletion with BRIUMVI in approximately 60 patients with treatment-resistant schizophrenia based on emerging evidence linking immune dysfunction to disease in a subset of patients Phase 2 trial to evaluate the effects of B-cell depletion with BRIUMVI in approximately 60 patients with treatment-resistant schizophrenia based on emerging evidence linking immune dysfunction to disease in a subset of patients

GlobeNewsWire • Jul 6, 2026

Will Briumvi's Strength Continue to Aid TGTX's Top Line in Q2?

TG Therapeutics continues to witness rising Briumvi demand. Investors are closely watching the sales numbers of the drug.

Zacks Investment Research • Jul 3, 2026

TG Therapeutics Stock Rises Thursday: What's Driving The Gains?

TG Therapeutics Inc. (NASDAQ:TGTX) shares are trading higher on Thursday as traders keep leaning into recent upbeat clinical updates around BRIUMVI.

Benzinga • Jun 18, 2026

TG Therapeutics Stock Is On A Hot Streak: Why It's Up 70% And Climbing

TG Therapeutics stock is on an absolute rampage, climbing 70% in roughly the first six months of the year, as the biotech takes on Roche.

Investors Business Daily • Jun 17, 2026

TG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock?

TG Therapeutics (TGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Investment Research • Jun 11, 2026

TGTX Rises on Positive Phase I Data for Subcutaneous Briumvi in MG

TG Therapeutics gains after positive phase I data for subcutaneous Briumvi in myasthenia gravis or MG, while a phase II study in MG gets underway.

Zacks Investment Research • Jun 10, 2026

TG Therapeutics, Inc. (TGTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

TG Therapeutics, Inc. (TGTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • Jun 9, 2026

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial

82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-ADL observed in Phase 1 study of Subcutaneous BRIUMVI in patients with MG (n=11)

GlobeNewsWire • Jun 9, 2026